RYE, N.Y., Aug. 9, 2013 /PRNewswire/ -- Curemark, a drug research and development company focused on neurological disorders, announced that the company has been awarded a new patent for its proprietary technology CM-1212 for the treatment of individuals with drug and alcohol addiction. The new patent, #8,486,390, is entitled "Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Methods of Diagnosing the Same." It is the third in a series of patent grants for this indication.
"Physiological symptoms of drug and alcohol addiction involve impairments in protein breakdown caused by a lack of key enzymes. These symptoms have not been identified nor addressed in the current treatment and management of addiction," said Dr. Joan Fallon, Curemark founder and CEO. "The ability to identify and treat individuals with these contributory or resulting symptoms is a big step. We believe Curemark's findings on the effects of impairments in protein breakdown on the brain will provide new understanding of the complex factors of addiction."
Curemark is currently developing a treatment for autism, CM-AT, which the U.S. Food and Drug Administration (FDA) has granted its Fast Track designation. The FDA Fast Track program facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to meet unmet medical needs.
Curemark previously announced successful preliminary discussions with the FDA regarding the anticipated future filing of the company's New Drug Application (NDA) for CM-AT.
About Curemark LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastroi
|SOURCE Curemark LLC|
Copyright©2012 PR Newswire.
All rights reserved